Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 106 to 120 of 1002 results for public health medicine & health

  1. Reducing sexually transmitted infections (NG221)

    This guideline covers interventions to prevent sexually transmitted infections (STIs) in people aged 16 and over. It aims to reduce the transmission of all STIs, including HIV, and includes ways to help increase the uptake of STI testing and vaccines for human papillomavirus (HPV) and hepatitis A and B.

  2. Lifileucel for previously treated unresectable or metastatic melanoma [ID3863]

    In development Reference number: GID-TA10752 Expected publication date: TBC

  3. Durvalumab with platinum-based chemotherapy, then with or without olaparib, for treating newly diagnosed advanced or recurrent endometrial cancer [ID6317]

    In development Reference number: GID-TA11340 Expected publication date: TBC

  4. Hydromethylthionine mesylate for treating mild cognitive impairment or mild or moderate dementia caused by Alzheimer's disease [ID6343]

    In development Reference number: GID-TA11379 Expected publication date: TBC

  5. Ibrutinib with R-CHOP for untreated mantle cell lymphoma when an autologous stem cell transplant is suitable [ID6596]: draft guidance

    We are listening to your views on this Technology appraisal guidance. Comments close 21 July 2026.

  6. Zuranolone for treating postnatal depression [ID6431]

    In development Reference number: GID-TA11356 Expected publication date: TBC

  7. Social, emotional and mental wellbeing in primary and secondary education (NG223)

    This guideline covers ways to support social, emotional and mental wellbeing in children and young people in primary and secondary education (key stages 1 to 5), and people 25 years and under with special educational needs or disability in further education colleges. It aims to promote good social, emotional and psychological health to protect children and young people against behavioural and health problems.

  8. Larotrectinib for treating NTRK fusion-positive advanced solid tumours (MA review of TA630) [ID6292]

    In development Reference number: GID-TA11565 Expected publication date:  18 November 2026

  9. Olezarsen for treating familial chylomicronaemia syndrome [ID6585]

    In development Reference number: GID-TA11678 Expected publication date:  26 August 2026

  10. Avapritinib for treating inadequately controlled moderate to severe indolent systemic mastocytosis [ID6578]

    In development Reference number: GID-TA11772 Expected publication date: TBC

  11. Aficamten for treating symptomatic obstructive hypertrophic cardiomyopathy [ID6575]: final draft guidance

    We are listening to your views on this Technology appraisal guidance. Comments close 9 July 2026.

  12. Aficamten for treating symptomatic obstructive hypertrophic cardiomyopathy [ID6575]

    In development Reference number: GID-TA11742 Expected publication date: TBC

  13. Maternal and child nutrition: nutrition and weight management in pregnancy, and nutrition in children up to 5 years (NG247)

    This guideline covers nutrition and weight management in pregnancy for anyone who may become pregnant, is planning to become pregnant or is already pregnant, and nutrition in children up to 5 years. Care of babies and children born preterm or with low birth weight is not covered. The guideline does not give detailed advice on what constitutes a healthy diet.

  14. Pirtobrutinib for untreated chronic lymphocytic leukaemia or small lymphocytic lymphoma [ID6397]

    In development Reference number: GID-TA11501 Expected publication date: TBC

  15. Medicines for treating osteoporosis and reducing the risk of fragility fractures (review of TA160, TA161, TA204, TA464, TA791, TA991) [ID6689]

    Awaiting development Reference number: GID-TA11907 Expected publication date:  10 June 2027